Is TMB a good predictive biomarker for immunotherapy?
Evidence is compelling, but utility may depend on the clinical context
TILs show long-term efficacy in melanoma, but predicting treatment response is still a challenge
After proof of efficacy in patients with melanoma in a clinical trial, major efforts are now directed to make the use of TILs easier and safer in clinical practice.
Blocking GDF-15 may be promising to overcome resistance to immunotherapy
A study reports evidence of antitumour activity by combining a GDF-15 neutralising antibody with PD-1 inhibition in cancers that are refractory/relapsed to immune checkpoint inhibitors
Lenvatinib plus pembrolizumab does not improve outcomes in NSCLC
Certain immunotherapy combinations that are effective in selected solid tumours may not be effective in lung cancer without targetable genetic alterations.
Challenges in cell-based immunotherapies create opportunities for progress
According to the 2023 ESMO Immuno-Oncology Awardee, Steven A. Rosenberg, the keys to progress are identifying the optimal characteristics of antitumour effector lymphocytes, cancer antigen identification and strategies for overcoming resistance mechanisms to enhance immune-cell function
Preventive immunotherapy shows some activity in pre-cancer oral lesions
A phase II trial opens up discussions on how to define success of chemoprevention studies
New models show promise for predicting response to treatment in HER2-positive breast cancer
Personalisation of treatment could be a step closer by integrating several cancer characteristics, but consolidation of data from these tools is needed before their use in clinical practice
The value of real-world data to inform cancer research and care
Well-designed real-world observational studies are hypothesis-generating and impact therapeutic decisions
Additional data confirm the promise of combination therapies for EGFR-mutated NSCLC
Analysis from MARIPOSA-2 and FLAURA2 trials show a potential change of treatment paradigm in both first- and second-line settings
New Pan-Asian-adapted recommendations on gastric cancer and early breast cancer presented by ESMO
The two Pan-Asian Guideline Adaptations of parental ESMO Clinical Practice Guidelines reflect the younger age of disease occurrence and lack of some treatment data in Asia